Stay informed with the latest litigation news. Explore now

IP Verse

Fred Hutchinson Cancer Center patent opposition analysis

Latest patents of Fred Hutchinson Cancer Center New

Explore the latest patents granted to Fred Hutchinson Cancer Center, showcasing their recent innovations and technological advancements.

Last updated on: Aug 31, 2025
Patent NumberGrant DateTitleLegal Status

Get instant update for new patents of Fred Hutchinson Cancer Center

EP3688157
Apr 27, 2022High Efficiency Targeted In Situ Genome-Wide ProfilingGranted And Under Opposition
EP3636778
Jan 12, 2022Agents For Use In Treating Facioscapulohumeral Dystrophy (Fshd)Revoked
EP3363901
Dec 30, 2020Compositions And Methods For Accurately Identifying MutationsGranted And Under Opposition
EP2689010
Nov 18, 2020Method And Compositions For Cellular ImmunotherapyGranted And Under Opposition
EP2884999
Nov 4, 2020Method And Compositions For Cellular ImmunotherapyGranted And Under Opposition
EP2814959
Jan 17, 2018Compositions And Methods For Accurately Identifying MutationsRevoked

Latest patents of Fred Hutchinson Cancer Center opposed by its competitors

Explore Fred Hutchinson Cancer Center's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 4, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3688157
Apr 27, 2022High Efficiency Targeted In Situ Genome-Wide Profiling1
EP3636778
Jan 12, 2022Agents For Use In Treating Facioscapulohumeral Dystrophy (Fshd)2
EP3363901
Dec 30, 2020Compositions And Methods For Accurately Identifying Mutations3
EP2689010
Nov 18, 2020Method And Compositions For Cellular Immunotherapy1
EP2884999
Nov 4, 2020Method And Compositions For Cellular Immunotherapy1
EP2814959
Jan 17, 2018Compositions And Methods For Accurately Identifying Mutations1

Top competitors of Fred Hutchinson Cancer Center

Top competitors of Fred Hutchinson Cancer Center based on patent oppositions.